BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

BioN­Tech has high­ly en­cour­ag­ing sur­vival da­ta for its bis­pe­cif­ic an­ti­body com­bin­ing check­point block­ade with VEGF-A in­hi­bi­tion as a first-line treat­ment for a se­ri­ous form of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER